drugset
drugset / Trial / NCT06221462

Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer

NCT06221462 ↗

Phase 2 Not yet recruiting 30 enrolled Ningbo No.2 Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective single-center, open-label, phase II study evaluating the efficacy of sintilimab plus anlotinib as a neoadjuvant regimen in the treatment of IB-IIIB resectable non-small cell lung cancer.

Timeline

Start
2024-02-01
Primary completion
2025-02-28
Completion
2030-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 8 mg Oral
Subject Sintilimab Monoclonal antibody 200 mg —

Indications

non-small cell lung carcinoma